MX2012008989A - Metodos de sintetizacion y aislamiento de n-(bromoacetil)-3,3-dini troazetidina y composicion que incluye la misma. - Google Patents

Metodos de sintetizacion y aislamiento de n-(bromoacetil)-3,3-dini troazetidina y composicion que incluye la misma.

Info

Publication number
MX2012008989A
MX2012008989A MX2012008989A MX2012008989A MX2012008989A MX 2012008989 A MX2012008989 A MX 2012008989A MX 2012008989 A MX2012008989 A MX 2012008989A MX 2012008989 A MX2012008989 A MX 2012008989A MX 2012008989 A MX2012008989 A MX 2012008989A
Authority
MX
Mexico
Prior art keywords
abdnaz
bromoacetyl
synthesizing
isolating
dnaz
Prior art date
Application number
MX2012008989A
Other languages
English (en)
Inventor
Nicholas A Straessler
Louis F Cannizzo
Ping Li
Michael P Kramer
David M Rosenberg
Original Assignee
Alliant Techsystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliant Techsystems Inc filed Critical Alliant Techsystems Inc
Publication of MX2012008989A publication Critical patent/MX2012008989A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un método de sintetización y aislamiento de la N-(bromoacetil)-3,3-dinitroazetidina (ABDNAZ) haciendo reaccionar el DNAZ con bromuro de brornoacetilo y el eterato del trifluoruro de boro en un solvente para producir una mezcla que comprende el ABDNAZ y una sal de DNAZ. Se agregan agua y un volumen adicional del solvente a la mezcla para formar una fase orgánica que comprende la ABDNAZ y una fase acuosa que comprende la sal de DNAZ. La fase orgánica y la fase acuosa son separadas para producir la solución de ABDNAZ/solvente que comprende la ABDNAZ y la fase acuosa que comprende la sal de DNAZ. Se agrega una substancia no solvente a la solución de ABDNAZ/solvente para producir una mezcla de ABDNAZ/solvente/substa ncia no solvente. El ABDNAZ es recuperado subsiguientemente. También se describe una composición que comprende la ABDNAZ.
MX2012008989A 2010-02-09 2011-01-18 Metodos de sintetizacion y aislamiento de n-(bromoacetil)-3,3-dini troazetidina y composicion que incluye la misma. MX2012008989A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/702,782 US8471041B2 (en) 2010-02-09 2010-02-09 Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
PCT/US2011/021500 WO2011100090A1 (en) 2010-02-09 2011-01-18 Methods of synthesizing and isolating n-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same

Publications (1)

Publication Number Publication Date
MX2012008989A true MX2012008989A (es) 2012-08-23

Family

ID=43875262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008989A MX2012008989A (es) 2010-02-09 2011-01-18 Metodos de sintetizacion y aislamiento de n-(bromoacetil)-3,3-dini troazetidina y composicion que incluye la misma.

Country Status (12)

Country Link
US (1) US8471041B2 (es)
EP (1) EP2534131B1 (es)
JP (1) JP5461712B2 (es)
KR (1) KR101456438B1 (es)
CN (1) CN102762535B (es)
AU (1) AU2011216176B2 (es)
CA (1) CA2788459C (es)
DK (1) DK2534131T3 (es)
ES (1) ES2460040T3 (es)
IL (1) IL221141A (es)
MX (1) MX2012008989A (es)
WO (1) WO2011100090A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
EP2763667B1 (en) 2011-10-07 2022-10-26 EpicentRx, Inc. Organonitro thioether compounds and medical uses thereof
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
ES2880482T3 (es) 2016-01-11 2021-11-24 Epicentrx Inc Composiciones y métodos para la administración intravenosa de 2-bromo-1-(3,3-dinitroazetidin-1-il)etanona
AU2017342436C1 (en) 2016-10-14 2022-11-03 Epicentrx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CN117835979A (zh) * 2021-06-09 2024-04-05 埃皮辛特瑞柯斯公司 结晶abdnaz组合物以及其制备和使用方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
JPS60116642A (ja) 1983-11-29 1985-06-24 Nippon Kayaku Co Ltd ２−モノ−置換メチル−５，５−ジメチル−シクロ−２−ヘキセノン誘導体
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
GB8728418D0 (en) * 1987-12-04 1988-01-13 Jenkins T C Nitro-substituted aromatic/hetero-aromatic compounds for use in cancer treatment
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5693794A (en) * 1988-09-30 1997-12-02 The United States Of America As Represented By The Secretary Of The Navy Caged polynitramine compound
JP2659614B2 (ja) * 1990-11-13 1997-09-30 株式会社日立製作所 表示制御装置
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5336784A (en) * 1993-06-07 1994-08-09 The Regents Of The University Of California Synthesis of 1,3,3-trinitroazetidine
ES2292402T3 (es) 1994-05-27 2008-03-16 Strakan International Limited Composicion de donador de oxido nitrico y metodo para el tratamiento de afecciones anales.
IL117474A (en) * 1995-03-14 2001-04-30 Siemens Ag Removable precise dosing unit containing inhaled drugs for a hearing aid device
IL117473A (en) * 1995-03-14 2001-08-26 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
WO1996036602A1 (en) 1995-05-15 1996-11-21 The United States Of America Adnaz, compositions and processes
US5580988A (en) * 1995-05-15 1996-12-03 The United States Of America As Represented By The Secretary Of The Army Substituted azetidines and processes of using them
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
JP2001501159A (ja) 1996-10-15 2001-01-30 イーストマン ケミカル カンパニー 爆薬配合物
GB9720797D0 (en) 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6056966A (en) * 1998-05-18 2000-05-02 Baker Norton Pharmaceuticals, Inc. Method and compositions for treating impotence
CA2337690C (en) 1998-07-27 2013-10-01 Texas Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6245799B1 (en) * 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
KR20020087134A (ko) 2000-04-10 2002-11-21 화이자 프로덕츠 인크. 벤조아미드 피페리딘 함유 화합물 및 관련 화합물
US6861530B2 (en) * 2000-07-07 2005-03-01 Kyowa Hakko Kogyo Co., Ltd. Piperidine derivatives
DE10111049A1 (de) 2001-03-06 2002-09-12 Beiersdorf Ag Verwendung von Substanzen, die verhindern, daß die NO-Synthese des warmblütigen Organismus ihre Wirkung entfaltet, zur Herstellung von kosmetischen oder dermatologischen Zubereitungen, zur Prophylaxe und Behandlung von entzündlichen Hautzuständen und/oder zum Hautschutz bei empfindlich determinierter trockener Haut
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US7163958B2 (en) * 2002-07-03 2007-01-16 Nitromed Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2501625A1 (en) 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
US6870061B2 (en) * 2003-01-10 2005-03-22 Alliant Techsystems Inc. Continuous process and system for production of glycidyl nitrate from glycerin, nitric acid and caustic and conversion of glycidyl nitrate to poly(glycidyl nitrate)
AU2004237574A1 (en) 2003-03-13 2004-11-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods of use
WO2004113281A1 (en) 2003-06-25 2004-12-29 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
GB0326047D0 (en) 2003-11-07 2003-12-10 Univ Sheffield Substance
AU2005282241B2 (en) * 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) * 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
CA2623034A1 (en) * 2005-09-27 2007-04-05 Novartis Ag Carboxyamine compounds and their use in the treatment of hdac dependent diseases
KR100967848B1 (ko) * 2008-05-28 2010-07-05 국방과학연구소 분자화약이 도입된, 고에너지 결합제용1-글리시딜-3,3-디니트로아제티딘 및 그의 제조방법
US20120149678A1 (en) * 2010-12-09 2012-06-14 Oronsky Bryan T Organonitro Compounds for Use in Treating Non-Hodgkin's Lymphoma and Leukemia, and Methods Relating Thereto

Also Published As

Publication number Publication date
ES2460040T3 (es) 2014-05-13
KR20130053385A (ko) 2013-05-23
WO2011100090A1 (en) 2011-08-18
CA2788459A1 (en) 2011-08-18
JP5461712B2 (ja) 2014-04-02
CN102762535B (zh) 2014-09-03
AU2011216176A1 (en) 2012-08-23
AU2011216176B2 (en) 2013-11-14
IL221141A (en) 2016-08-31
KR101456438B1 (ko) 2014-10-31
EP2534131B1 (en) 2014-03-19
IL221141A0 (en) 2012-09-24
US20110195947A1 (en) 2011-08-11
US8471041B2 (en) 2013-06-25
JP2013518925A (ja) 2013-05-23
CN102762535A (zh) 2012-10-31
DK2534131T3 (da) 2014-04-07
CA2788459C (en) 2016-01-05
EP2534131A1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
MX2012008989A (es) Metodos de sintetizacion y aislamiento de n-(bromoacetil)-3,3-dini troazetidina y composicion que incluye la misma.
EA201591671A1 (ru) Аэрированные композиционные материалы, способы их получения и применения
EA201690405A1 (ru) Аэрированные композиционные материалы, способы их получения и применения
EA201291470A1 (ru) Замороженное кондитерское изделие
NZ734535A (en) Process of producing cycloalkylcarboxamido-indole compounds
UA110354C2 (uk) Противірусні сполуки
MY158251A (en) Method for the preparation of nalmefene hydrochloride
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
NZ609191A (en) Methods of making l-ornithine phenyl acetate
MX2013000773A (es) Procedimiento de preparacion de derivados de amino-benzoil-benzofu rano.
WO2012082672A3 (en) Process and intermediates for preparing macrolactams
MY167395A (en) Method for producing glufosinate p free acid
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
EP2524687A3 (en) Edible jelly-form composition, jelly-form preparation and method for producing jelly-form preparation
MY171201A (en) New carbamate glycolipid and use thereof
WO2014176469A3 (en) Improved methods for making ribosomes
WO2009138847A3 (en) An improved process for the preparation of cefozopran
MX2016003240A (es) Berbinas sustituidas y su sintesis.
MX2014008010A (es) Metodos para aislar 4-cloro-2-fluor-3-fenil boronatos sustituidos y métodos para su uso.
MX2019002620A (es) Métodos de síntesis química de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (mtc).
GB2482826A (en) Synthesis of morphine and related derivatives
WO2014115174A8 (en) Novel approach for synthesis of catechins
RU2014106990A (ru) Способы выделения 4-хлор-2-фтор-3-замещенных-фенилбороновых кислот
WO2012050315A3 (ko) Fp-cit 전구체로서의 아제티디늄 염, 이의 선택적 제조방법 및 fp-cit 의 합성
EP3290403A3 (en) Methods of producing molindone and its salts

Legal Events

Date Code Title Description
FG Grant or registration